← Research library

Clinical and immunologic effects of T-activin therapy in early stage melanoma patients.

Comparison in people · 1996

What was studied
17 melanoma patients: 8 surgery plus T-activin; 9 surgery-only controls
Main finding
In a 17-person melanoma comparison, the survival difference with T-activin added to surgery was not statistically significant; immune-cell changes did not track clinical benefit.

Reported survival time · 40 versus 24 months · T-activin + surgery versus surgery alone · Reported follow-up · Not statistically significant

Reported findings and study design

In a 17-person melanoma comparison, the survival difference with T-activin added to surgery was not statistically significant; immune-cell changes did not track clinical benefit.

T-activin + surgery 8; surgery alone 9; early-stage melanoma; follow-up February 1991–August 1995.

Results · Primary-publication indexed abstract; no full-text table appraisal
MeasureResultComparison, timing and statistics
Reported survival time40 versus 24 monthsT-activin + surgery versus surgery alone · Reported follow-up · Not statistically significant
Disease-free interval17.5 versus 13 monthsSame comparison; described as similar
Lymphoproliferative responseIncrease in 4 of 5 treated patients with progressionBiological response did not correspond to clinical benefit
Participants8 treated; 9 controls

The survival-time summary is not labeled as a median in the abstract. The small, non-randomized study does not establish a cancer-survival benefit.

Source for these results ↗ · Reviewed 2026-11-01

Study limitations and source details

Study limitations

  • Very small adjunctive comparison; random allocation and blinding are not established by the abstract.
  • Immune-marker changes did not correlate with clinical course and should not be presented as proven cancer benefit.

Source details

Journal article

Original publication metadata and indexed abstract checked; full methods and tables not appraised.

Indexed abstract reviewed

Sources checked

Citation

Human comparative studyEnglish abstract

N. Stanojević-Bakić, D. Milosević, L. Vucković-Dekić, M. Sasić, L. Marković. Clinical and immunologic effects of T-activin therapy in early stage melanoma patients. Neoplasma. 43(4):245–252

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards